Additionally, an analysis demonstrated a significant reduction in gastric cancer (GC) risk with Proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors (12), underscoring the potential of lipid-lowering therapies in cancer prevention. This evidence concerns the gene PCSK9 and cancer.